Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Objective Study in Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2008-09-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 249
- Registration Number
- NCT00451971
- Locations
- 🇦🇺
Sanofi-Aventis, Sydney, Australia
Open Label, Phase I ZD6474 Head and Neck Cancer Study
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT00450138
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2007-03-20
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 508
- Registration Number
- NCT00449605
- Locations
- 🇨🇱
Sanofi-aventis adminsitrative office, Santiago, Chile
🇸🇪Sanofi-Aventis Administrative Office, Bromma, Sweden
Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)
- Conditions
- Rhinitis, Allergic, Perennial
- Interventions
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2012-08-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 299
- Registration Number
- NCT00449072
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Preventing Antibiotic-Associated DiarRhea Using Erceflora
- Conditions
- Diarrhea, Infantile
- Interventions
- Drug: Bacillus Clausii Multi ATB ResistDrug: Placebo
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2008-09-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 323
- Registration Number
- NCT00447161
- Locations
- 🇵🇭
Sanofi-Aventis, Manila, Philippines
Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 127
- Registration Number
- NCT00446030
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance
- Conditions
- Malaria
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 300
- Registration Number
- NCT00445796
- Locations
- 🇸🇳
Sanofi-Aventis, Dakar, Senegal
Irbesartan/Hydrochlorothiazide National Taiwan University Hospital Listing
- Conditions
- Hypertension
- Interventions
- Drug: Irbesartan/HydrochlorothiazideDrug: Irbesartan
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2009-10-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT00443612
- Locations
- 🇨🇳
Sanofi-Aventis, Taipei, Taiwan
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
- Conditions
- Intermittent Claudication
- Interventions
- First Posted Date
- 2007-03-05
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 553
- Registration Number
- NCT00443287
- Locations
- 🇿🇦
Sanofi-Aventis Administrative Office, Midrand, South Africa
Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age
- Conditions
- Japanese Encephalitis
- Interventions
- Biological: ChimeriVax™-JEBiological: Japanese Encephalitis Inactivated Mouse Brain Vaccine
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2012-08-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 96
- Registration Number
- NCT00441259
- Locations
- 🇮🇳
Maulana Azad Medical College, New Delhi, India
🇮🇳Government Medical College, Baroda, India
🇮🇳Dr Atul's Child Hospital, Jaipur, Rajasthan, India